Literature DB >> 29766466

Concurrent isolated IgG2-positive membranous nephropathy and malignant B-cell lymphoma.

Satoshi Shimada1, Takashi Nakamichi2, Gen Yamada1, Kaori Narumi1, Hajime Usubuchi3, Tae Yamamoto1, Satoshi Ichikawa4, Noriko Fukuhara4, Mariko Miyazaki1, Hideo Harigae4, Hiroshi Sato1, Sadayoshi Ito1.   

Abstract

A recent systematic review showed that hematological malignancy is often complicated by membranous nephropathy (MN). Histologically, the deposition of IgG subclasses other than IgG4 may imply secondary MN, such as malignancy-associated MN (M-MN). We describe a very rare case of concurrent isolated IgG2-positive MN and B-cell lymphoma. An 83-year-old woman was hospitalized at our institute for facial and lower extremity edema persisting for 2 months. Laboratory tests showed urinary protein level of 10.8 g/day, serum albumin level of 1.6 g/dl, and serum creatinine level of 2.34 mg/dl. Soon after diagnosis of nephrotic syndrome, treatment with corticosteroid was initiated, but it proved to be ineffective. Renal biopsy showed isolated IgG2-positive MN with highly infiltrated CD20-positive lymphoid cells in the kidney. Computed tomography revealed systemic lymphadenopathy, and aberrant B-cells with immunoglobulin light chain restriction were detected in peripheral blood and bone marrow, which led to the diagnosis of mature B-cell lymphoma. Although rituximab (375 mg/m2/week) was administered, the patient suddenly died from gastrointestinal bleeding on day 40 of hospitalization. It is, thus, necessary to consider hematological malignancy when a diagnosis of MN is made. Further studies are expected to elucidate the pathogenesis and to help establish the adequate treatment for this rare situation.

Entities:  

Keywords:  B-cell lymphoma; Isolated IgG2-positive; Membranous nephropathy; Rituximab

Mesh:

Substances:

Year:  2018        PMID: 29766466      PMCID: PMC6181876          DOI: 10.1007/s13730-018-0336-z

Source DB:  PubMed          Journal:  CEN Case Rep        ISSN: 2192-4449


  18 in total

1.  Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis.

Authors:  Alessia Fornoni; Junichiro Sageshima; Changli Wei; Sandra Merscher-Gomez; Robier Aguillon-Prada; Alexandra N Jauregui; Jing Li; Adela Mattiazzi; Gaetano Ciancio; Linda Chen; Gaston Zilleruelo; Carolyn Abitbol; Jayanthi Chandar; Wacheree Seeherunvong; Camillo Ricordi; Masami Ikehata; Maria Pia Rastaldi; Jochen Reiser; George W Burke
Journal:  Sci Transl Med       Date:  2011-06-01       Impact factor: 17.956

2.  Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.

Authors:  R Stasi; E Stipa; G Del Poeta; S Amadori; A C Newland; D Provan
Journal:  Rheumatology (Oxford)       Date:  2006-04-21       Impact factor: 7.580

Review 3.  Pathogenesis, diagnosis and management of paraneoplastic glomerulonephritis.

Authors:  Yeong-Hau H Lien; Li-Wen Lai
Journal:  Nat Rev Nephrol       Date:  2010-12-14       Impact factor: 28.314

4.  Proliferative glomerulonephritis with monoclonal IgG2κ deposit successfully treated with steroids: a case report and review of the literature.

Authors:  Ryuji Ohashi; Yukinao Sakai; Tomoyuki Otsuka; Dai Ohno; Yukinari Masuda; Tsuneo Murasawa; Naoki Sato; Akira Shimizu
Journal:  CEN Case Rep       Date:  2013-02-26

5.  Rituximab therapy for steroid-dependent minimal change nephrotic syndrome.

Authors:  Rodney D Gilbert; Eleanor Hulse; Susan Rigden
Journal:  Pediatr Nephrol       Date:  2006-08-24       Impact factor: 3.714

6.  Case report: therapeutic transcatheter embolotherapy in the control of recurrent haemorrhage from lymphoma of the small bowel.

Authors:  D C Howlett; M M Farrugia; A T Irvine
Journal:  Br J Radiol       Date:  1995-04       Impact factor: 3.039

7.  Distribution of IgG subclasses in membranous nephropathy.

Authors:  T Doi; M Mayumi; K Kanatsu; F Suehiro; Y Hamashima
Journal:  Clin Exp Immunol       Date:  1984-10       Impact factor: 4.330

8.  B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab.

Authors:  R John Looney; Jennifer H Anolik; Debbie Campbell; Raymond E Felgar; Faith Young; Lois J Arend; James A Sloand; Joseph Rosenblatt; Iñaki Sanz
Journal:  Arthritis Rheum       Date:  2004-08

9.  Primary lymphoma of the small intestine. A clinicopathological study of 119 cases.

Authors:  P Domizio; R A Owen; N A Shepherd; I C Talbot; A J Norton
Journal:  Am J Surg Pathol       Date:  1993-05       Impact factor: 6.394

10.  Rituximab for idiopathic membranous nephropathy.

Authors:  Giuseppe Remuzzi; Carlos Chiurchiu; Mauro Abbate; Verusca Brusegan; Mario Bontempelli; Piero Ruggenenti
Journal:  Lancet       Date:  2002-09-21       Impact factor: 79.321

View more
  1 in total

1.  Network analysis of membranous glomerulonephritis based on metabolomics data.

Authors:  Amir Taherkhani; Shiva Kalantari; Afsaneh Arefi Oskouie; Mohsen Nafar; Mohammad Taghizadeh; Koorosh Tabar
Journal:  Mol Med Rep       Date:  2018-09-12       Impact factor: 2.952

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.